The synergy between DNA damage and BCL-2 inhibition in MCPyV-positive cell lines provides an explanation for why downregulation of BCL-2 mRNA alone was insufficient to impede tumor growth in patients with metastatic or regionally recurrent MCC [33]. The gene discussed is BCL2; the disease is neoplasm.